Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors
Anusha Kalbasi(Stanford Medicine), K. Christopher García(Brigham and Women's Hospital), Warren J. Leonard(National Heart Lung and Blood Institute), Enrico Radaelli(University of Pennsylvania), Philipp C. Rommel(University of Pennsylvania), Amy Sun(University of California, Los Angeles), Leon Su(Stanford University), Sangya Agarwal(Amgen (United States)), Pranali Ravikumar(Parker Institute for Cancer Immunotherapy), Lora K. Picton(Stanford University), Mikko Siurala(Parker Institute for Cancer Immunotherapy), Decheng Song(University of Pennsylvania), Mito Tariveranmoshabad(University of California, Los Angeles), Helena Escuin-Ordinas(University of California, Los Angeles), Sarah Kremer(University of California, Los Angeles), Regina M. Young(University of Pennsylvania), Antoni Ribas(University of California, Los Angeles), John Scholler(University of Pennsylvania), Peng Li(National Institutes of Health), Tong Da(University of Pennsylvania), Sofia Castelli(Drexel University), Jian‐Xin Lin(National Heart Lung and Blood Institute), Carl H. June(University of Pennsylvania)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k